mitotic

Alisertib (MLN 8237) is a specific Aurora A inhibitor (IC50: 1.2 nM). The selectivity of Alisertib(MLN 8237) is >200-fold higher for Aurora A than Aurora B.

BRD9876 is a selective inhibitor of MM1S growth.

MT 63-78 is a specific and effective direct AMPK activator (EC50: 25 μM) that blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. It has antitumor effects and induces cell mitotic arrest and apoptosis.

Colcemid (NSC-3096) is a microtubule polymerization inhibitor that primarily targets tubulin, with an IC₅₀ of 2.4 μM. Demecolcine interacts with tubulin dimers, induces antimitotic effects, and inhibits microtubule growth. Colcemid is a classic reagent used in karyotyping, banding techniques, and cell cycle synchronization. Colcemid can induce apoptosis and is used in studies of tumor and embryonic cloning.

Maytansine (NSC-153858), an ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata, inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site.

KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.

Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM).

BO-264 is a highly potent and orally active inhibitor of transforming acidic coiled-coil 3 (TACC3) with an IC50 of 188 nM and a Kd of 1.5 nM.

TC11 (1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11) is a potent inhibitor of tumor cell proliferation and an inducer of apoptosis via activation of caspase-3, 8 and 9.

Scoulerine is an inhibitor of ß-site amyloid precursor protein cleaving enzyme 1(BACE1). Scoulerine a potent antimitotic compound that inhibits proliferation, arrests cell cycle, and induces apoptosis in cancer cells.

(-)-Epipodophyllotoxin (2) is an antiproliferative agent targeting cancer cells, exhibiting GI50 values of 0.36 μM in HeLa cells and 0.24 μM in MCF-7 cells, and inhibiting mitotic spindle assembly in vitro.

R1530 is a multikinase inhibitor with antineoplastic and antiangiogenesis activities.

Mitotic kinesin-IN-3 (Page 135, fourteenth) hydrochloride is an inhibitor of the mitotic motor protein (Mitotickinesin). It interferes with cell proliferation by inhibiting mitosis. This compound can be utilized in research relating to cancer, cardiac hypertrophy, immune and inflammatory diseases, as well as fungal infections.

Mitotic kinesin-IN-2 (Page 135, fifteenth) hydrochloride is an inhibitor of mitotic motor proteins (Mitotickinesin). This compound suppresses cell proliferation by inhibiting mitosis. Mitotic kinesin-IN-2 hydrochloride is used in research related to cancer, cardiac hypertrophy, immune and inflammatory diseases, as well as fungal infections.

Mitotic kinesin-IN-1 hydrochloride (Example 80) is an inhibitor of mitotic kinesin, which suppresses cell proliferation by hindering mitosis. This compound is applicable in research related to cancer, cardiac hypertrophy, immune and inflammatory diseases, and fungal infections.

Sovilnesib is a kinesin-like protein KIF18A inhibitor. Sovilnesib can be used for the cancer research.

BTB-1 (NSC156750) is a novel small molecule inhibitor of the mitotic motor protein Kif18A.

AM-5308 is a kinesin KIF18A inhibitor that can be used to study cancer.

ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.

CHR-6494 TFA is a potent haspin inhibitor with an IC50 of 2 nM, inhibiting histone H3T3 phosphorylation. It induces apoptosis in cancer cells, including melanoma and breast cancer, and is useful for cancer research.

LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest.

Antimitotic agent-2 (Compound 1) is an antimitotic agent that inhibits the proliferation of human epidermal cells. It may be used in the treatment of hyperproliferative skin disorders.

DMU-212 is a methylated derivative of resveratrol with antimitotic, anti-proliferative, antioxidant, and apoptosis-promoting activities. It induces mitotic arrest, apoptosis, and activation of ERK1/2 protein and has oral activity[1][2]. DMU-212 (0.3125-40 μM) inhibits the growth of human melanoma cells (A375, MeWo, Bro, M5)[1]. At concentrations of 30-50 μM over 24 hours, it upregulates cell cycle inhibitors, induces apoptosis, and activates ERK in A375 cells[1]. DMU-212 also induces G2/M arrest and apoptosis in cancer cells[1]. In a xenograft model of human ovarian cancer with six-week-old SCID female mice (20-24 g), DMU-212 (50 mg/kg, administered orally three times a week for 14 days) inhibits tumor growth[2]. [1]. Vasilis Pericles Androutsopoulos, et al. Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4'-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 2015 Aug;24(8):632-4. [2]. Hanna Piotrowska, et al. DMU-212 inhibits tumor growth in xenograft model of human ovarian cancer. Biomed Pharmacother. 2014 May;68(4):397-400.

Vinorelbine ditartrate (KW-2307) is a natural alkaloid and an anti-mitotic agent. Vinorelbine ditartrate has anti-tumor activity, inhibiting cell proliferation and inducing apoptosis.